Shares of Medallia (NASDAQ:MDLA) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokers have set a one year consensus price target of $43.00 for the company and are predicting that the company will post ($0.02) EPS for the current quarter, according to Zacks. Zacks has also given Medallia an industry rank of 76 out of 256 based on the ratings given to its competitors.

Separately, Stifel Nicolaus downgraded Viveve Medical from a “buy” rating to a “hold” rating and cut their price target for the company from $3.00 to $1.00 in a report on Monday, July 22nd.

Shares of NASDAQ:MDLA traded down $0.50 on Wednesday, reaching $43.00. The company had a trading volume of 2,800 shares, compared to its average volume of 2,185,500. Medallia has a 52-week low of $32.05 and a 52-week high of $44.72.

In other news, Director Borge Hald sold 1,765,000 shares of Medallia stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $19.53, for a total value of $34,470,450.00. The sale was disclosed in a filing with the SEC, which is available through this link.

About Medallia

Medallia, Inc provides an enterprise Software-as-a-Service platform in North America, Europe, the Middle East, Africa, and internationally. The company's platform utilizes deep learning-based artificial intelligence technology to analyze structured and unstructured data from signal fields in human, digital, and Internet of Things interactions.

Featured Story: Put Option Volume

Get a free copy of the Zacks research report on Medallia (MDLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medallia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medallia and related companies with MarketBeat.com's FREE daily email newsletter.